Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) FCF Margin (2016 - 2025)

Historic FCF Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 33.05%.

  • Ptc Therapeutics' FCF Margin rose 63400.0% to 33.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.64%, marking a year-over-year increase of 657300.0%. This contributed to the annual value of 14.15% for FY2024, which is 57700.0% up from last year.
  • Latest data reveals that Ptc Therapeutics reported FCF Margin of 33.05% as of Q3 2025, which was up 63400.0% from 33.35% recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' FCF Margin ranged from a high of 73.84% in Q1 2025 and a low of 104.28% during Q4 2022
  • For the 5-year period, Ptc Therapeutics' FCF Margin averaged around 29.85%, with its median value being 33.44% (2021).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -608300bps in 2021, then soared by 698100bps in 2023.
  • Over the past 5 years, Ptc Therapeutics' FCF Margin (Quarter) stood at 46.94% in 2021, then crashed by -122bps to 104.28% in 2022, then soared by 67bps to 34.47% in 2023, then surged by 54bps to 15.84% in 2024, then tumbled by -109bps to 33.05% in 2025.
  • Its FCF Margin stands at 33.05% for Q3 2025, versus 33.35% for Q2 2025 and 73.84% for Q1 2025.